Biomarkers · Lipids & Apolipoproteins
Lipoprotein(a) [Lp(a)]
Lower values carry lower risk. Not measured in our NHANES panel; the curve is synthesised from the published association.
Hazard ratio relative to the curve's reference value, as synthesised from the published association.
Published hazard ratio1.22top vs bottom third (95% CI 1.13–1.32) · Emerging Risk Factors Collaboration (36 Prospective Studies)
Where people sit
Population percentiles (nmol/L) by sex and age band. Cycle or source as recorded in the catalogue.
| Sex | Age | 5th | 25th | Median | 75th | 95th | n | Cycle / source |
|---|---|---|---|---|---|---|---|---|
| All | 20-39 | 3.80 | 9.00 | 19.5 | 45.0 | 158 | 1,580 | 2017-2018 |
| All | 40-59 | 4.20 | 10.2 | 21.4 | 49.0 | 167 | 1,560 | 2017-2018 |
| All | 60+ | 4.50 | 10.8 | 22.5 | 51.0 | 172 | 1,660 | 2017-2018 |
| All | all | 4.00 | 10.0 | 21.0 | 48.0 | 165 | 4,800 | 2017-2018 |
| Men | all | 4.00 | 9.50 | 20.0 | 46.0 | 160 | 2,350 | 2017-2018 |
| Women | all | 4.50 | 10.5 | 22.0 | 50.0 | 170 | 2,450 | 2017-2018 |
What studies found when this marker was changed
Effects on the biomarker reported in the cited studies. They describe what happened in those populations, not a recommendation for anyone. See all catalogued interventions.
| Type | Intervention | Reported effect | Evidence | Source |
|---|---|---|---|---|
| clinical | Genetically low LPA Kringle IV type 2 copy number variants | +200% to +1000% inherited elevation (>100 mg/dL) | prospective cohort | Clarke R, et al. N Engl J Med. 2009;361:2518-2528. |
| pharmacologic | Novel RNA-targeting therapeutics (Pelacarsen, Olpasiran) or PCSK9 inhibitors | Reduces circulating Lp(a) by 20-30% (PCSK9i) up to 80-95% (siRNA/ASO) | RCT | Ridker PM, et al. Rosuvastatin to prevent vascular events in men and women with … |
| pharmacologic | Antisense oligonucleotide / siRNA inhibitors (Pelacarsen / Olpasiran) | -70% to -95% profound reduction | rct | O'Donoghue ML, et al. N Engl J Med. 2022;387:1855-1864. |
| pharmacologic | PCSK9 monoclonal antibodies (Evolocumab / Alirocumab) | -25% to -35% reduction | meta-analysis | Bittner VA, et al. J Am Coll Cardiol. 2020;75:133-144. |
| pharmacologic | Niacin therapy (Extended release 1500-2000 mg) | -20% to -30% reduction | rct | Carlson LA. J Intern Med. 2005;258:94-114. |
| physiological | Postmenopausal hormone depletion and estrogen deficiency | +15% to +30% elevation post-menopause | prospective cohort | Kimak E, et al. Clin Biochem. 2008;41:744-749. |